A call for more transparency of registered clinical trials on endometriosis

Sun Wei Guo*, Lone Hummelshoj, David L. Olive, Serdar E. Bulun, Thomas M. D'Hooghe, Johannes L.H. Evers

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


In response to the pressing need for more efficacious and safer therapeutics for endometriosis, there have been numerous reports in the last decade of positive results from animal and in vitro studies of various compounds as potential therapeutics for endometriosis. A handful of these have undergone phase II/III clinical trials. Since the announcement of the International Committee of Medical Journal Editors that mandated registration as a prerequisite for publication, 57 endometriosis-related clinical trials have been registered at ClinicalTrials.gov, an Internet-based public depository for information on drug studies. Among them, 25 are listed as completed, and 2 as suspended. There are 15 completed phase II/III trials, which evaluated the efficacy of various promising compounds. Yet only three of the 15 trials (20) have published their results. The remaining 12 (80) studies so far have not published their findings. We argue that this apparent lack of transparency will actually not benefit the trial sponsors or the public, and will ultimately prove detrimental to research efforts attempting to develop more efficacious and safer therapeutics for endometriosis. Thus we call for more transparency of clinical trials on endometriosis.

Original languageEnglish (US)
Pages (from-to)1247-1254
Number of pages8
JournalHuman Reproduction
Issue number6
StatePublished - Jun 2009


  • Clinical trial
  • Disclosure
  • Endometriosis
  • Registration
  • Transparency

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'A call for more transparency of registered clinical trials on endometriosis'. Together they form a unique fingerprint.

Cite this